Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Pterine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 10/20 | 0.51 |
| ▸ | MITF | O75030 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | HBB | P68871 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | NOS1 | P29475 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | PNP | P00491 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pterine SCHEMBL23295082 | 0.91 | AKR1B1 (0.55) | AKR1B1MITFTP53THRBALOX15 | |
| Pterine SCHEMBL9444227 | 0.91 | AKR1B1 (0.59) | AKR1B1MITFTP53THRBALOX15 | |
| Pterine SCHEMBL64320 | 0.91 | AKR1B1 (0.54) | AKR1B1MITFTP53THRBALOX15 | |
| Pterine SCHEMBL29364680 | 0.91 | AKR1B1 (0.54) | AKR1B1MITFTP53THRBALOX15 | |
| Pterine SCHEMBL27777837 | 0.91 | POLB (0.47) | AKR1B1MITFTP53THRBALOX15 | |
| Pterine SCHEMBL906054 | 0.90 | AKR1B1 (0.53) | AKR1B1MITFTP53THRBALOX15 | |
| Pterine SCHEMBL5703596 | 0.90 | AKR1B1 (0.53) | AKR1B1MITFTP53THRBALOX15 | |
| Pterine SCHEMBL31190985 | 0.90 | AKR1B1 (0.53) | AKR1B1MITFTP53THRBALOX15 | |
| Pterine SCHEMBL31296557 | 0.90 | AKR1B1 (0.53) | AKR1B1MITFTP53THRBALOX15 | |
| Pterine SCHEMBL30474634 | 0.90 | AKR1B1 (0.53) | AKR1B1MITFTP53THRBALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120076830-A | Peptide-based delivery agents and methods of making and using the same | 恩多雷尔生物科学有限责任公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-119709713-A | Cofactor 2 protein gene ZmCNX2 of corn nitrate reductase and xanthine dehydrogenase and application thereof | 吉林大学 | 2025-03-28 | — | — | CN | disclosed |
| CN-112135791-B | Organically modified mineral particles, method for the production and use thereof | 禾大国际股份公开有限公司 | 2024-01-26 | — | — | CN | disclosed |
| CN-112135791-A | Organically modified mineral particles, method for the production thereof and use thereof | 禾大国际股份公开有限公司 | 2020-12-25 | — | — | CN | disclosed |
| US-8486374-B2 | Alcohol-free drug or cosmetics carrier mixture of water, hydrophobic solvent, surfactant and gelling agent; oil in water emulsions | FOAMIX LTD. (IL) | 2013-07-16 | — | — | US | disclosed |
| CN-102766165-A | Methods for synthesizing molybdopterin precursor z derivatives | ALEXION PHARMA INC | 2012-11-07 | — | — | CN | disclosed |
| US-20080299220-A1 | HYDROPHILIC, NON-AQUEOUS PHARMACEUTICAL CARRIERS AND COMPOSITIONS AND USES | VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.) | 2008-12-04 | — | — | US | disclosed |
| US-20080292560-A1 | SILICONE IN GLYCOL PHARMACEUTICAL AND COSMETIC COMPOSITIONS WITH ACCOMMODATING AGENT | FOAMIX PHARMACEUTICALS LTD. (IL) | 2008-11-27 | — | — | US | disclosed |
| US-20080206161-A1 | QUIESCENT FOAMABLE COMPOSITIONS, STEROIDS, KITS AND USES THEREOF | FOAMIX PHARMACEUTICALS LTD. (IL) | 2008-08-28 | — | — | US | disclosed |
| US-20080069779-A1 | Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof | FOAMIX LTD. (IL) | 2008-03-20 | — | — | US | disclosed |
| EP-1373482-A2 | CRYSTALS OF KETOPANTOATE HYDROXYMETHYLTRANSFERASE | Astex Technology Limited (GB) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002079460-A2 | CRYSTALS OF KETOPANTOATE HYDROXYMETHYL TRANSFERASE | ASTEX TECHNOLOGY LIMITED (GB) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080206161-A1 | QUIESCENT FOAMABLE COMPOSITIONS, STEROIDS, KITS AND USES THEREOF | NR5A1, CYP17A1, LIPA | AKR1B1 606/4885MITF 3792/4885TP53 1672/4885 |
| US-20080292560-A1 | SILICONE IN GLYCOL PHARMACEUTICAL AND COSMETIC COMPOSITIONS WITH ACCOMMODATING AGENT | SSTR2, SSTR3, LPXN | AKR1B1 2352/4885MITF 13/4885TP53 345/4885 |
| US-20080069779-A1 | Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof | PROC, VKORC1, TTPA | AKR1B1 361/4885MITF 1489/4885TP53 896/4885 |
| US-20080299220-A1 | HYDROPHILIC, NON-AQUEOUS PHARMACEUTICAL CARRIERS AND COMPOSITIONS AND USES | LIPA, PHOSPHO1, MYO1G | AKR1B1 4419/4885MITF 1057/4885TP53 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.